| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: AVRX |
| Security Type |
Common Stock |
| Lead Underwriter |
WR Hambrecht & Co LLC |
| Days In Registration |
149 |
| Date Filed |
3-May-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Avalon Pharmaceuticals Inc, located in Germantown, Maryland, is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class cancer therapeutics. Its flagship product, AVN944, an IMPDH inhibitor, is in Phase II clinical development, while its late stage preclinical programs include inhibitors of the Beta-catenin and Aurora/Centrosome pathways, discovery programs for inhibitors of the Survivin and Myc pathways. The company was founded in 1999. |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
8.4M |
| Contact |
- |
| Number of Employees |
43 |
|
| Original Filing Information |
| US |
| Shares Filed |
4.5M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
4.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
412.5K |
| File Amount |
$49.5M |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
Current Filing Information
(Amended 22-Sep-2005) |
|
US |
|
Shares Filed |
2.75M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
2.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$30.25M |
| · % Change from Original |
-38.89 |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
|
